Part the Cloud Translational Research for Alzheimer’s Disease Program: Combination Therapies Program (PTC-CTP)
Funds clinical trials testing at least two biomarker-driven therapeutic combinations for Alzheimer’s disease, emphasizing innovative, mechanistic research and rigorous scientific rationale.
Funder: Alzheimer's Association
Due Dates (Anticipated): March 2027: Letter of Intent deadline (projected) | April 2027: Full application deadline (projected)
Funding Amounts: Phase 1: up to $1,000,000 total costs; Phase 2-3: up to $2,000,000 (rarely $3,000,000) total costs over 2–3 years; indirect costs capped at 10% for nonprofits only.
Summary: Supports combination clinical trials for Alzheimer’s disease testing at least two therapeutic approaches, emphasizing biomarker-driven design and rigorous scientific rationale.
Key Information: This is a forecasted, annually recurring opportunity; all dates are projected—check the program page for updates.
Description
This program provides funding for translational research clinical trials that evaluate combination therapies for Alzheimer’s disease and related dementias. Eligible projects must test at least two therapeutic approaches (e.g., drug-drug, drug-behavioral, drug-device) and should be designed with a strong biological rationale, robust biomarker-based inclusion criteria and outcomes, and clear justification for the combination strategy. The program prioritizes studies that advance innovative, biomarker-informed therapies and require applicants to articulate the study population, endpoints, statistical plan, safety monitoring, and decision criteria for further development. Proposals must also address how anti-amyloid monoclonal antibody treatments are incorporated or considered within the trial design.
